Scancell Share Discussion Threads

[serratia] 03/3/2023 22:01

Checking out the competition -

I came across Transgene, any views good or bad ?

[marcusl2] 03/3/2023 15:33

it is the antibodies, notably GlyMabs, that we view as less well understood and certainly under-appreciated. The recent deal with Genmab, a highly respected antibody developer, serves to validate the GlyMab approach and suggests the direct and potent anti-tumour activity seen in preclinical models could translate to the clinic.

SC134 is a redirecting T cell bispecific undergoing functional analysis and targets fucosyl GM1, with an initial focus on small cell lung cancer (SCLC). Fucosyl-GM1 is known to be expressed in up to 90% of SCLC and, unlike many other lung cancer antigens, has little or no expression in normal tissues. It is completing preclinical studies and is currently on target to enter the clinic in H224.

SC88 is in lead candidate selection and targets Lewisacx with a view to addressing colorectal cancer. The cell-based studies again showed highly specific target binding with little off-target effects.

SC27 is in functional analysis targeting Lewisy for gastric cancers. Preclinical studies have shown it to be more selective and potent than previous Lewisy targeting approaches.

The fifth mAb, SC2811, is a mAb that stimulates tumour infiltrating T cells. It is undergoing target validation for glycolipid stage-specific embryonic antigen 4 (SSEA4) on human and mouse T stem memory cells. It could have clinical value in many solid tumours. An AvidiMab modified ultra-specific lead candidate is expected to be selected during H123.

valuation to £300.1m, or 36.7p

[torquayfan] 03/3/2023 15:25

Inan - keep going.

Your 'style' has led to a lot of Inan baiting and when you reply, it never ends.

I know you think it's fun but your more important messages are diffused - if that's the right word ?

Peace Brothers -

[panama7] 03/3/2023 14:15

For all you vaccine enthusiasts where do you think Moditope fits into the future of vaccines.....

[markingtime] 03/3/2023 13:54

.....more delusional nonsense. Possibly explained by his apparent emergence as a world expert on syphilis.....?

[inanaco] 03/3/2023 11:34

you have already seen that Ivy ... changed his posts on the LSE because of my intervention

but if you feel that Ivy "statements" should never be questioned

what is the point of having any discussion ....

we already see that Ruck and MT are desperate to be in a position that posts are not challenged

why do you see this freedom of speech as such a threat ?

[inanaco] 03/3/2023 11:27

I am not arguing DC ....

presenting factual posts ...

[dominiccummings] 03/3/2023 11:22

Go away to the argument thread Inanaco

[inanaco] 03/3/2023 11:14

Since the protective immune response in
syphilis is delayed hypersensitivity (DTH), whatever immunogen is selected it should be constructed to induce DTH

you cannot get a better statement than that .........

[inanaco] 03/3/2023 11:13

At the site of contact, about two weeks after infection, there is a firm raised
inflammatory reaction characterized by central necrosis, called
a chancre. This is the result of a delayed hypersensitivity
reaction characterized by lymphocytic infiltration followed by
an influx of macrophages that phagocytose and destroy the
invading T. pallidum [191,192]. This is evidence of a strong
CD4 + T-cell immunity and after healing of the chancre there
is strong resistance to reinfection (chancre immunity).

[inanaco] 03/3/2023 10:30

Because SCIB1 and Keytruda have shown efficacy, we need quite a few patients to separate a clear divergence from using Keytruda alone.

we are also changing the product shortly .....

if Iscib1 has improved efficacy and can be used in every melanoma patient, then that divergence from known statistical data from the keytruda trials will appear faster

Scancell switching from Ichor to gene gun also makes the product far more attractive to patients and Big Pharma

[markingtime] 03/3/2023 10:06

Re SCIB1, whilst everyone obsesses (not unreasonably) with Modi-1 and has a casual interest in Covidity's future (which will be triggered by a Scancell paper on the topic), the rest of the portfolio seems to be slipping under the radar.MaBs news can come any time, but any views on the likely timeframe for news on other fronts?

[markingtime] 03/3/2023 09:59

Precisely, RuckRover. It is tiresome beyond belief.

[inanaco] 03/3/2023 09:56

As we are on the subject of Dilution again


this is an interesting post .... again perhaps Ruck can explain "what is the Company" or "what is Scancell"

AND THAT THE Ip GETS SLICED UP WITH THE COMPANY as the company owns it .

ATB


Bermudashorts - 16 Sep 2021 - 08:16:10 - 44690 of 56939 Using immunology to fight cancer. - SCLP
Inanaco,

Can't you see that neither is correct?

The IP per se has not been diluted or affected in any way by the issue of new equity. It's your share of the ownership of the Company that's been diluted, the percentage of the company that you own. You can argue until the cows come home about how you value the company but if you take it back to basics, all you're aruguing about is the impact of the dilution.

[inanaco] 03/3/2023 08:47

Ivy clearly has not calculated the share price that he is predicting related to the Mcap

lets call it mid range ..... 50p ...

= £400m Mcap approx

cash raise i estimate at £30m

not exactly a threat is it ....

[inanaco] 03/3/2023 08:44

I see Scancell raising funds to carry Modi2 etc into the clinic is now a "threat"

from Ivy post on the LSE "Glycan deal which will remove this particular threat"

I covered dilution recently for this very reason

[marcusl2] 03/3/2023 08:41

Bermudashorts

SCIB1 clinical trial
The SCIB1 trial record has been updated - Royal Free London added as a study centre but not yet recruiting and Plymouth now open for recruitment.

[inanaco] 03/3/2023 08:32

yes that thread contains Marking time thoughts on Ruckrover

not pleasant reading

[marcusl2] 03/3/2023 08:22

Guys you are ruining this thread. Please go to the other one for arguments.

[inanaco] 03/3/2023 08:15

Please Note

Marking Time ... seems to be a little angry person

advice

Do not give him alcohol

Do Not discuss politics

Never Question his posts ... you will be classed as an "idiot"

[markingtime] 03/3/2023 08:01

See the shrink, FFS!

[inanaco] 03/3/2023 08:00

Ivy has been telling us right through the pandemic that he is a valued expert in Virus vaccines having being in the industry for 15 years ..

this was actually endorsed by Bermuda .....

ATB

it took Ivy 15 years to learn "less" than I learned in 30 mins about his own products that he sells